II Seminário Paulista de autismo 2010

II Seminário Paulista de autismo 2010

02 outubro 2011

Study Looks at Beta Blocker Drug Therapy for Autism

By RICK NAUERT PHD Senior News Editor
Reviewed by John M. Grohol, Psy.D. on September 30, 2011
Study Looks at Beta Blocker Drug Therapy for AutismFor those with autismmedications are called for when the individual presents specific psychiatric problems such as aggression, anxiety and obsessive behavior.
University of Missouri researchers believe propranolol (a drug long used to treat high blood pressure and control heart rate as well as to reduce test anxiety) offers potential for improving language and social function, two of the three primary traits associated with autism, along with repetitive behaviors.
“We can clearly say that propranolol has the potential to benefit language and may help people with autism function appropriately in social situations, including making eye contact with others,” said David Beversdorf, M.D.
“Enhancing both language and social function is significant because those are two of the three main features of autism. Clinical trials will assess the drug’s effect on all three features, including repetitive behaviors.”
Propranolol is a well-tolerated drug that has been has been used for decades in healthy individuals. The study by MU researchers is the first to study the benefits of the drug in autism in a controlled manner.
Researchers will now conduct clinical trials to determine if the benefits are sustained over time and if the benefits outweigh other effects.
Pharmacologically, propranolol acts by reducing the effect of norepinephrine brought on by stress in order to allow the brain to function as if there is no stress.
Experts say this is why the drug helps people who have trouble with test taking.
In people with autism, the brain is hardwired in a different way, making processing more rigid in terms of social function and language. The researchers think that the drug acts on these hardwired processes and therefore, improves tasks and functioning in these areas.
“When healthy persons are under stress their neurons fire in an expedited manner, to respond quickly to the stressor, that does not allow input from remote sources,” Beversdorf said. Unfortunately when trying to solve difficult problems, we need information from remote sources. For example, if we come in contact with a tiger, we are programmed to respond quickly and run away.
“However, this fight or flight response isn’t as helpful in today’s society because instead of facing a tiger, we are taking an exam or giving a speech.
“Evidence suggests that individuals with autism have a similar difficulty accessing input from remote sources regardless of the presence of stress when using language and communicating.”
Earlier investigation demonstrated that propranolol helped people with autism solve simple anagrams or word unscrambling tasks. It also increased word fluency, which requires understanding the definition of words and connectivity among different brain regions.
It did not help with letter fluency, which involves identifying words that start with specific letters and requires less distributed connectivity among brain regions.
“We are interested to see if we can predict who will or will not respond to this drug among those with autism,” Beversdorf said.
“In the follow-up study, we’re looking at markers of increased stress reactivity. If we find that those with higher stress reactivity are more sensitive to the effects of propranolol, it might help to identify who will benefit most from the drug.”
The findings are published in the journal Cognitive and Behavior Neurology.